4.0 Article

Tonometric devices for central aortic systolic pressure measurements in patients with type 1 diabetes: comparison of the BPro and SphygmoCor devices

Journal

BLOOD PRESSURE MONITORING
Volume 18, Issue 3, Pages 156-160

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MBP.0b013e328360fb19

Keywords

central aortic systolic pressure; diabetes; tonometry

Ask authors/readers for more resources

Objective Central blood pressure may be a better risk marker than brachial blood pressure and can be measured noninvasively by tonometric devices. We investigate whether tonometric measurements are feasible in patients with diabetes and whether the degree of albuminuria or increased arterial stiffness affects measurements. Patients and methods In 676 patients with type 1 diabetes, comparison of central aortic systolic pressure (CASP) measurements by the BPro and the SphygmoCor devices were made. The BPro device can obtain both office and 24-h measurements, whereas the SphygmoCor device is an accepted device for CASP measurements. Results Measurements of CASP with both BPro and SphygmoCor were available in 598 (88.5%) patients (mean age 54 years; mean diabetes duration 33 years; 45.2% women), and mean +/- SD of CASP was 122 +/- 17 and 118 +/- 17 mmHg, respectively (P < 0.001). Linear and intraclass correlation coefficients between CASP estimated from BPro and SphygmoCor were r equal to 0.96 and 0.95 (P< 0.001 for both). The mean +/- SD difference between devices was 3.6 +/- 4.8mmHg (P < 0.001). Analyses according to the level of albuminuria or degree of arterial stiffness were confirmatory. Conclusion In patients with type 1 diabetes, tonometric measurements of CASP with BPro and SphygmoCor showed strong correlations, although values differed by similar to 4mmHg between devices. Level of CASP, arterial stiffness, and degree of albuminuria did not interfere with the agreement between devices. In addition, the BPro device can obtain 24-h measurements and may thus be useful to assess the diurnal patterns of CASP. (c) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Transplantation

Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)

Jennifer B. Green, Amy K. Mottl, George Bakris, Hiddo J. L. Heerspink, Johannes F. E. Mann, Janet B. McGill, Masaomi Nangaku, Peter Rossing, Charlie Scott, Alain Gay, Rajiv Agarwal

Summary: This study aims to investigate the efficacy of dual therapy with finerenone and an SGLT2i in reducing chronic kidney disease and type 2 diabetes. The results will provide important insights for improving treatment methods for kidney disease and cardiovascular risks.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Article Endocrinology & Metabolism

Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use

Peter Rossing, Rajiv Agarwal, Stefan D. Anker, Gerasimos Filippatos, Bertram Pitt, Luis M. Ruilope, Vivian Fonseca, Guillermo E. Umpierrez, Maria Luiza Caramori, Amer Joseph, Marc Lambelet, Robert Lawatscheck, George L. Bakris

Summary: This study investigated the effect of GLP-1RA use on the outcomes of patients with CKD and T2D treated with finerenone. The results showed that the use of GLP-1RA did not affect the cardiorenal benefits of finerenone.

DIABETES OBESITY & METABOLISM (2023)

Article Endocrinology & Metabolism

In vivo molecular imaging of cardiac angiogenesis in persons with and without type 2 diabetes: A cross-sectional 68 Ga-RGD-PET study

Jens Christian Laursen, Ida Kirstine Bull Rasmussen, Emilie Hein Zobel, Philip Hasbak, Lene Holmvang, Christian Stevns Hansen, Bernt Johan von Scholten, Marie Frimodt-Moller, Peter Rossing, Tine Willum Hansen, Andreas Kjaer, Rasmus Sejersten Ripa

Summary: Cardiac angiogenesis assessed by Ga-68-RGD PET was similar in type 2 diabetes and non-diabetic controls, and was not associated with kidney function or other risk factors.

DIABETIC MEDICINE (2023)

Article Medicine, General & Internal

Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update

Sankar D. Navaneethan, Sophia Zoungas, M. Luiza Caramori, Juliana C. N. Chan, Hiddo J. L. Heerspink, Clint Hurst, Adrian Liew, Erin D. Michos, Wasiu A. Olowu, Tami Sadusky, Nikhil Tandon, Katherine R. Tuttle, Christoph Wanner, Katy G. Wilkens, Jonathan C. Craig, David J. Tunnicliffe, Marcello Tonelli, Michael Cheung, Amy Earley, Peter Rossing, Ian H. de Boer, Kamlesh Khunti

Summary: The KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease is an update of the 2020 guideline. The guideline was updated based on reviewing new evidence and using the GRADE approach to assess evidence and develop consensus practice points. The recommendations were updated in the areas of comprehensive care and glucose-lowering therapies, while recommendations in the areas of glycemic monitoring, lifestyle interventions, and management approaches remained unchanged.

ANNALS OF INTERNAL MEDICINE (2023)

Article Medicine, General & Internal

Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease: A Post Hoc Analysis of DAPA-CKD

Meir Schechter, Niels Jongs, Glenn M. Chertow, Ofri Mosenzon, John J. McMurray, Ricardo Correa-Rotter, Peter Rossing, Anna Maria Langkilde, C. David Sjostrom, Robert D. Toto, David C. Wheeler, Hiddo J. L. Heerspink

Summary: This study aimed to determine the effects of dapagliflozin on hospitalizations in patients with chronic kidney disease (CKD). The results showed that dapagliflozin reduced the risk of hospitalization for any cause in patients with CKD, regardless of whether they had type 2 diabetes or not.

ANNALS OF INTERNAL MEDICINE (2023)

Article Endocrinology & Metabolism

Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial

Viktor Rotbain Curovic, Niels Jongs, Marjolein Y. A. M. Kroonen, Emilie H. Zobel, Tine W. Hansen, Taha Sen, Gozewijn D. Laverman, Adriaan Kooy, Frederik Persson, Peter Rossing, Hiddo J. L. Heerspink

Summary: This randomized crossover trial found significant variation in participants' responses to different drug classes in terms of urinary albumin to creatinine ratio (UACR) reduction. The results suggest that systematic rotation through different drug classes can overcome resistance to RAS inhibitors.

DIABETES CARE (2023)

Review Peripheral Vascular Disease

What did we learn from the International Databases on Ambulatory and Home Blood Pressure in Relation to Cardiovascular Outcome?

Kei Asayama, Katarzyna Stolarz-Skrzypek, Wen-Yi Yang, Tine W. Hansen, Jana Brguljan-Hitij, Augustine N. Odili, Yan Li, Jan A. Staessen

Summary: The International Databases on Ambulatory (IDACO) and Home (IDHOCO) Blood Pressure in Relation to Cardiovascular Outcome conducted a meta-analysis which found that 24-hour and nighttime blood pressure levels are the best predictors of adverse health outcomes. They also established corresponding thresholds for home and ambulatory blood pressure. The study emphasized the importance of out-of-office blood pressure monitoring in tackling the hypertension pandemic.

HYPERTENSION RESEARCH (2023)

Article Transplantation

The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease

Peter Rossing, Florian M. M. Baeres, George Bakris, Heidrun Bosch-Traberg, Mette Gislum, Stephen C. L. Gough, Thomas Idorn, Jack Lawson, Kenneth W. Mahaffey, Johannes F. E. Mann, Henriette Mersebach, Vlado Perkovic, Katherine Tuttle, Richard Pratley, FLOW Steering Comm, FLOW Trial Investigators

Summary: This study aims to investigate the effects of semaglutide on kidney outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). The participants were found to be mostly at high risk for CKD progression. The study is expected to be completed in late 2024.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Article Multidisciplinary Sciences

Marker for kidney fibrosis is associated with inflammation and deterioration of kidney function in people with type 2 diabetes and microalbuminuria

Christina Gjerlev W. Poulsen, Daniel G. K. Rasmussen, Federica Genovese, Tine Hansen, Signe Holm K. Nielsen, Henrik Reinhard, Bernt Johan von Scholten, Peter Jacobsen, Hans-Henrik Parving, Morten Asser Karsdal, Peter Rossing, Marie Frimodt-Moller

Summary: This study investigated whether C3M, a degradation product of collagen type III, is a risk marker for the progression of chronic kidney disease (CKD) in individuals with type 2 diabetes and microalbuminuria. The results showed that higher levels of sC3M were associated with CKD progression in these patients.

PLOS ONE (2023)

Article Genetics & Heredity

Differential Methylation of Telomere-Related Genes Is Associated with Kidney Disease in Individuals with Type 1 Diabetes

Claire Hill, Seamus M. Duffy, Laura Kettyle, Liane McGlynn, Niina M. Sandholm, Rany Salem, Alex J. Thompson, Elizabeth Swan, Jill Kilner, Peter G. Rossing, Paul Shiels, Maria Lajer, Per-Henrik Groop, Alexander Peter Maxwell, Amy Jayne McKnight, GENIE Consortium

Summary: Diabetic kidney disease (DKD) is a major global health problem characterized by accelerated aging. This study explored features affecting telomere biology and methylation dysregulation in DKD using multi-omics approaches, which may provide useful biomarkers or therapeutic targets.

GENES (2023)

Article Endocrinology & Metabolism

Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial

Hiddo J. L. Heerspink, Andreas L. Birkenfeld, David Z. I. Cherney, Helen M. Colhoun, Linong Ji, Chantal Mathieu, Per-Henrik Groop, Richard E. Pratley, Sylvia E. Rosas, Peter Rossing, Jay S. Skyler, Katherine R. Tuttle, Robert Lawatscheck, Charlie Scott, Robert Edfors, Markus F. Scheerer, Peter Kolkhof, Janet B. McGill

Summary: This study aims to evaluate the efficacy and safety of Finerenone in type 1 diabetes and chronic kidney disease (CKD). Finerenone could potentially become the first registered treatment for CKD associated with type 1 diabetes in almost 30 years.

DIABETES RESEARCH AND CLINICAL PRACTICE (2023)

Article Endocrinology & Metabolism

Glucagon-like peptide-1 treatment reduces the risk of diabetes-type 2 related amputations: A cohort study in Denmark

Zeinab Schafer, Andreas Mathisen, Trine Rolighed Thomsen, Peter Rossing, Klaus Kirketerp-Moller

Summary: This study conducted a cohort analysis on 309,116 patients with type 2 diabetes and found that GLP-1 agonist treatment significantly reduces the risk of lower extremity amputations, particularly among middle-income patients.

DIABETES RESEARCH AND CLINICAL PRACTICE (2023)

Review Endocrinology & Metabolism

Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes

Vikas S. Sridhar, Christine P. Limonte, Per-Henrik Groop, Hiddo J. L. Heerspink, Richard E. Pratley, Peter Rossing, Jay S. Skyler, David Z. I. Cherney

Summary: The current management of CKD in type 1 diabetes focuses on blood sugar control, inhibiting the renin-angiotensin system and optimizing risk factors. However, individuals with type 1 diabetes and CKD still face elevated risks for kidney and cardiovascular events. Novel therapies used in type 2 diabetes, such as sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists, have shown potential kidney and heart protection. Applying these therapies to individuals with type 1 diabetes for the prevention of CKD is of great importance.

DIABETOLOGIA (2023)

Article Urology & Nephrology

Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials

Robert A. Fletcher, Niels Jongs, Glenn M. Chertow, John J. V. Mcmurray, Clare Arnott, Meg J. Jardine, Kenneth W. Mahaffey, Vlado Perkovic, Patrick Rockenschaub, Peter Rossing, Ricardo Correa-Rotter, Robert D. Toto, Muthiah Vaduganathan, David C. Wheeler, Hiddo J. L. Heerspink, Brendon L. Neuen

Summary: This study analyzed the effect of SGLT2 inhibitors on the discontinuation of RAS blockade and found that patients receiving SGLT2 inhibitors had a lower risk of discontinuing RAS blockade. This effect was particularly pronounced in patients with a high baseline urinary albumin-to-creatinine ratio.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2023)

Article Cardiac & Cardiovascular Systems

Prognostic value of myocardial performance index in individuals with type 1 and type 2 diabetes: Thousand&1 and Thousand&2 studies

Hashmat Sayed Zohori Bahrami, Peter Godsk Jorgensen, Jens Dahlgaard Hove, Ulrik Dixen, Tor Biering-Sorensen, Peter Rossing, Magnus T. Jensen

Summary: Cardiovascular disease is the leading cause of death in type 1 and type 2 diabetes patients. The myocardial performance index (MPI), which reflects left ventricular function, has not been evaluated for its prognostic value in diabetes populations. This study evaluated two prospective cohort studies and found that MPI is associated with major adverse cardiovascular events and heart failure, particularly in type 1 diabetes patients, and improves prediction in this group.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING (2023)

No Data Available